Institut De Recherches Internationales Servier

This early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the drug daily un…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests two different drugs in adults with a rare type of bone marrow cancer called myelodysplastic syndromes (MDS) that has a specific genetic change (IDH1 mutation). Participants have not received a common first treatment (HMA) before. They will be randomly assigned to…

This study tests a new medicine (S230815) for children aged 2-12 with a rare, severe epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can help control seizures. About 20 children will take part, receiving the drug through a spinal injection…